Deciphera Pharmaceuticals (DCPH)

Executive Summary

Deciphera Pharmaceuticals is a publicly traded biotechnology company focused on developing and commercializing small-molecule kinase inhibitors for cancer. Its lead product, QINLOCK (ripretinib), is approved for advanced gastrointestinal stromal tumors (GIST) and continues to generate growing sales. The company's pipeline includes vimseltinib, a CSF1R inhibitor for tenosynovial giant cell tumor (TGCT), which is under FDA review with a PDUFA date in early 2026. Vimseltinib has demonstrated compelling efficacy and safety in Phase 3 data, positioning it as a potential near-term growth driver. Additionally, Deciphera is exploring earlier-stage programs targeting KRAS and other oncology pathways. With a commercial-stage product and a late-stage pipeline candidate, Deciphera offers a balanced risk-reward profile. However, competition in GIST and dependence on vimseltinib's approval introduce uncertainties. The company maintains a strong balance sheet to support operations and pipeline advancement.

Upcoming Catalysts (preview)

• Q2 2026FDA approval decision for vimseltinib in TGCT80% success
• TBDQINLOCK label expansion or new trial readout (e.g., in other sarcoma subtypes)40% success
• H2 2026Early-stage pipeline updates (e.g., KRAS inhibitor IND filing or Phase 1 data)50% success